Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ambit Biosciences gets $25mm in first tranche of Series E financing

Executive Summary

Ambit Biosciences Inc. (developing small-molecule kinase inhibitors for cancer) raised $25mm through the first tranche of its $50mm Series E round. All existing investors participated, including OrbiMed Advisors (which led and takes a seat on the company's board), Aisling Capital, Apposite Healthcare, Roche Venture Fund, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Proceeds will go towards the company's lead candidate quizartinib (AC220), an FMS-like tyrosine kinase-3 inhibitor that is in Phase II trials (with partner Astellas Pharma) for relapsed or refractory acute myeloid leukemia and treatment-naive AML.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies